Investorideas.com

Call 800 665 0411 to learn about our services

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS


 


BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology, telemedicine, Covid-19

Like Biotech Stocks? View our Biotech Stocks Directory    Get News Alerts on Biotech Stocks


Featured Biotech stocks - Feature Your Company & Product Here

Biotech News

Analyst Says Buy Before Biotech Co.'s Clinical Trials
September 26, 2022 (Investorideas.com Newswire) Argenx SE has "several upcoming catalysts," noted a Wedbush report. Argenx SE's (ARGX:NASDAQ) drug for generalized myasthenia gravis

Co.'s Clinical Program in HPV+ Cancers Gives It a Buy Rating
September 26, 2022 (Investorideas.com Newswire) To fund continued development of its lead immunotherapy candidate, the U.S.-based biopharma recently completed a $35 million debt financing agreement

Telemedicine Co. Says It's Set To Thrive in Post-Pandemic World
September 22, 2022 (Investorideas.com Newswire) The pandemic changed the way many people get their basic healthcare, giving a big opening to telemedicine companies like Reliq Health Technologies Inc.

Important Catalyst Expected Soon for Cancer Drug Co.
September 21, 2022 (Investorideas.com Newswire) The biopharma should announce initial clinical trial data on its lead small molecule candidate by year-end, noted a Wedbush report.

Dermatology Co.'s Target Price Much Larger Than Current
September 21, 2022 (Investorideas.com Newswire) The biopharma's strategic marketing campaign "should continue growing U.S. sales to current and new customers,"

Second Trial of New Eczema Drug To Commence in Q4/22
September 19, 2022 (Investorideas.com Newswire) The purpose behind this complementary study is to potentially expand the treatment's target patient population, noted an H.C. Wainwright & Co. report.

New Drug Shown To Help Patients With Desmoid Tumors
September 16, 2022 (Investorideas.com Newswire) This oral gamma-secretase inhibitor met the primary and secondary endpoints in a Phase 3 clinical trial, noted a Wedbush report.

Price Target on US Biopharma Co. Boosted by $15
September 16, 2022 (Investorideas.com Newswire) The increase came after positive clinical trial results on one of its lead drug candidates differentiating it from a competitor, noted a BTIG report.

Biotech Co.'s Target Six Times Current Price
September 15, 2022 (Investorideas.com Newswire) One Phase 2 clinical trial showing LSD reduced symptoms of anxiety bodes well for other studies of LSD in this indication.

Biotech Psilocybin Stock News: Nova Mentis (CSE: NOVA) Completes Production of Psilocybin Microdose Capsules
Vancouver, British Columbia - September 15, 2022 (Newsfile Corp.) (Investorideas.com Newswire) Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that it has completed production of psilocybin microdose capsules in collaboration with the Toronto Institute of Pharmaceutical Technology

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Other Ideas - Guest Posts and / or sponsored financial content

Learn how to be published on our site: Buy a guest post on Investorideas.com

Biotech News from Newsfile

Marvel Biosciences Announces Stock Option Grants
Calgary, Alberta--(Newsfile Corp. - September 26, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today announced that its board of directors has approved the grant of incentive stock options (the "Options") to certain directors and officers to acquire an aggregate of 1,425,000 common shares in the capital of the Company at an exercise price of $0.10, which is above the closing price of...

Zonetail Partners with Embedded Product Ordering Company MealMe to Boost Revenue

Zonetail will embed MealMe's technology into the Zonetail app to give users the ability to order 300M+ products from 1M+ local stores for pickup/ ultrafast delivery directly in the Zonetail app.

Toronto, Ontario--(Newsfile Corp. - September 26, 2022) - Zonetail Inc. (TSXV: ZONE) (OTCQB: ZTLLF) ("Zonetail") announces it has signed a groundbreaking agreement with MealMe, Inc. ("MealMe") a leader in embedded commerce technology. Zonetail is partnering with MealMe to allow users of the Zonetail mobile application to purchase over 300,000,000 food, beverages, and household items from over 1,000,000 local restaurants, grocery and retail stores directly within the Zonetail application. When users make a purchase on the...

Kiora Pharmaceuticals to Implement 1-for-40 Reverse Split
Salt Lake City, Utah--(Newsfile Corp. - September 26, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced that its stockholders authorized a reverse stock split of the Company's common stock. Following the annual stockholder meeting, the board of directors approved a reverse stock split of one share of common stock for every 40 shares of common stock. On The NASDAQ Capital Market, trading on a split-adjusted basis is expected to begin on...

NervGen Pharma Announces Leadership Transition
Bill Radvak, Co-founder and Executive Chairman of the Board, appointed interim Chief Executive Officer Dr. Adam Rogers, member of the Board of Directors, appointed interim President Paul Brennan to step down as President & Chief Executive Officer and member of the Board of Directors; will serve as a strategic advisor for a transition periodVancouver, British Columbia--(Newsfile Corp. - September 22, 2022) - NervGen Pharma Corp. (OTCQX: NGENF) (TSXV: NGEN), a clinical stage biotech company dedicated...

Solarvest BioEnergy Inc. Announces Grant of Stock Options, Re-Pricing of Existing Stock Options and Adoption of New Fixed Stock Option Plan
Vancouver, British Columbia--(Newsfile Corp. - September 22, 2022) - Solarvest BioEnergy Inc. (TSXV: SVS) ("Solarvest" or the "Company") announces that pursuant to the Company's existing Stock Option Plan, a total of 1,000,000 incentive stock options have been granted to a consultant of the Company. These stock options are exercisable at a price of $0.12 per share for a period of 2 years expiring August 1, 2024.The Company also wishes to announce that it intends to...

Subscribe to Biotech News